PHLCX Performance — PGIM Jennison Health Sciences Fund, Class C
Data updated: 2026-07-27
PHLCX returned −0.11% year to date and +30.02% over one year to May 2026. Annualised returns are +11.36% over 3 years and +5.63% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $138, against $131 for the category, and to $130 over one year, against $129. Volatility over the past three years was 15.10% a year. In the 12 months to May 2026 the fund lost a net $161.9M, and assets reached $1.39B.
PHLCX Growth of $100
What $100 invested in PGIM Jennison Health Sciences Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | PHLCX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $130 | $129 |
| 3 years (Jun 2023 – May 2026) | $138 | $131 |
| 5 years (Jun 2021 – May 2026) | $132 | $116 |
| Since data start (Sep 2019 – May 2026) | $203 | $173 |
PHLCX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −0.11% |
| 1 year | +30.02% |
| 3 years (annualised) | +11.36% |
| 5 years (annualised) | +5.63% |
PHLCX Annual Returns
Calendar-year total returns of PGIM Jennison Health Sciences Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | −0.11% |
| 2025 | +18.31% |
| 2024 | +7.54% |
| 2023 | +11.42% |
| 2022 | −11.06% |
| 2021 | +5.18% |
| 2020 | +40.24% |
| 2019 (Sep–Dec) | +9.46% |
PHLCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.7% | +2.1% | −6.0% | +0.4% | +5.5% | — | — | — | — | — | — | — |
| 2025 | +4.6% | −1.8% | −5.7% | −0.6% | −5.6% | +3.8% | −1.0% | +4.9% | +3.8% | +9.4% | +8.9% | −2.2% |
| 2024 | +4.2% | +6.1% | +2.0% | −6.4% | +2.4% | +2.7% | +3.2% | +5.4% | −3.9% | −3.3% | +1.6% | −5.7% |
| 2023 | +0.2% | −2.7% | +2.0% | +6.0% | −2.7% | +4.2% | −2.4% | +0.5% | −3.5% | −0.5% | +3.4% | +7.2% |
| 2022 | −12.9% | +0.9% | +4.4% | −8.3% | −2.1% | +0.7% | +4.4% | −4.7% | −3.6% | +6.7% | +4.1% | +0.5% |
| 2021 | +0.5% | −1.4% | −3.3% | +7.6% | −2.3% | +8.3% | 0.0% | +3.0% | −8.3% | +3.9% | −6.0% | +4.7% |
| 2020 | −2.2% | −3.7% | −8.3% | +15.8% | +9.3% | +2.2% | +1.5% | +4.9% | +2.7% | −3.8% | +10.3% | +8.3% |
| 2019 | — | — | — | — | — | — | — | — | −7.2% | +6.2% | +9.0% | +1.9% |
PHLCX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 15.10%
- 3-year Sharpe ratio: 0.45 (vs 4.5% risk-free rate)
- Best month: +9.36% (Oct 2025)
- Worst month: −6.40% (Apr 2024)
PHLCX Fund Flows
Monthly money in and out of PGIM Jennison Health Sciences Fund, from SEC Form N-PORT.
- 12-month net flow: −$161.9M
- 12-month gross sales (incl. reinvestments): $293.2M
- Sales ÷ redemptions: 0.64×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $8.5M | $33.0M | −$24.5M |
| Apr 2026 | $6.1M | $26.0M | −$19.9M |
| Mar 2026 | $7.8M | $27.4M | −$19.7M |
| Feb 2026 | $13.1M | $28.1M | −$15.0M |
| Jan 2026 | $17.2M | $34.4M | −$17.2M |
| Dec 2025 | $178.8M | $48.5M | $130.4M |
| Nov 2025 | $7.9M | $30.3M | −$22.3M |
| Oct 2025 | $7.9M | $43.9M | −$36.0M |
| Sep 2025 | $11.8M | $42.0M | −$30.2M |
| Aug 2025 | $13.5M | $44.3M | −$30.8M |
| Jul 2025 | $8.2M | $53.2M | −$45.0M |
| Jun 2025 | $12.3M | $44.0M | −$31.8M |
PHLCX Assets Under Management
Net assets of PGIM Jennison Health Sciences Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-29 | $1.39B |
| 2026-02-27 | $1.46B |
| 2025-11-28 | $1.56B |
| 2025-08-29 | $1.34B |
| 2025-05-30 | $1.34B |
| 2025-02-28 | $1.62B |
| 2024-11-29 | $1.76B |
| 2024-08-30 | $1.93B |
| 2024-05-31 | $1.75B |
| 2024-02-29 | $1.80B |
| 2023-11-30 | $1.55B |
| 2023-08-31 | $1.62B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.